Chris Shibutani

Stock Analyst at Goldman Sachs

(3.55)
# 840
Out of 5,154 analysts
94
Total ratings
55.1%
Success rate
22.17%
Average return

Stocks Rated by Chris Shibutani

Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $138$100
Current: $59.29
Upside: +68.66%
Erasca
Mar 21, 2025
Maintains: Buy
Price Target: $3.5$3
Current: $15.47
Upside: -80.61%
Seres Therapeutics
Mar 14, 2025
Maintains: Sell
Price Target: $20$15
Current: $9.13
Upside: +64.29%
Alkermes
Feb 14, 2025
Maintains: Buy
Price Target: $30$32
Current: $28.63
Upside: +11.77%
BioNTech SE
Nov 8, 2024
Upgrades: Buy
Price Target: $90$137
Current: $101.50
Upside: +34.98%
Syndax Pharmaceuticals
Nov 7, 2024
Maintains: Buy
Price Target: $30$33
Current: $22.07
Upside: +49.52%
United Therapeutics
Nov 1, 2024
Maintains: Neutral
Price Target: $243$302
Current: $478.16
Upside: -36.84%
Royalty Pharma
Aug 14, 2024
Maintains: Buy
Price Target: $50$51
Current: $45.41
Upside: +12.31%
Johnson & Johnson
Jul 19, 2024
Maintains: Neutral
Price Target: $160$155
Current: $240.40
Upside: -35.52%
Amylyx Pharmaceuticals
Jul 12, 2024
Maintains: Neutral
Price Target: $3$4
Current: $13.85
Upside: -71.12%
Maintains: Neutral
Price Target: $18$20
Current: $6.56
Upside: +204.88%
Maintains: Neutral
Price Target: $650$723
Current: $990.33
Upside: -26.99%
Maintains: Neutral
Price Target: $29$26
Current: $12.74
Upside: +104.08%
Maintains: Buy
Price Target: $134$153
Current: $128.13
Upside: +19.41%
Upgrades: Buy
Price Target: $173
Current: $230.11
Upside: -24.82%
Upgrades: Outperform
Price Target: n/a
Current: $70.70
Upside: -
Maintains: Buy
Price Target: $81$69
Current: $60.29
Upside: +14.45%
Maintains: Neutral
Price Target: $15$13
Current: $22.03
Upside: -40.99%
Maintains: Neutral
Price Target: $20$23
Current: $98.40
Upside: -76.63%
Maintains: Buy
Price Target: $40$52
Current: $83.49
Upside: -37.72%
Upgrades: Buy
Price Target: $47$60
Current: $27.05
Upside: +121.81%
Maintains: Neutral
Price Target: $13$18
Current: $12.58
Upside: +43.08%
Initiates: Buy
Price Target: $17
Current: $16.95
Upside: +0.29%
Initiates: Outperform
Price Target: n/a
Current: $6.19
Upside: -
Downgrades: Market Perform
Price Target: n/a
Current: $6.05
Upside: -